EsoCap Biotech

EsoCap to Present Key Phase II Results on Novel Drug Delivery System in Eosinophilic Esophagitis at DDW 2025

New insights on safety, adherence, and patient satisfaction with ESO-101 to be presented on May 3, 2025, at DDW 2025 ESO-101 features EsoCap’s proprietary drug delivery technology to enable localized treatment of the esophageal lining with the anti-inflammatory corticosteroid mometasone furoate The ACESO Phase II study underlines the importance of targeted drug delivery to the...
Malzgasse 9, CH-4052 Basel